Storage conditions：Short-term storage at 2~8℃, long-term storage at -20 ~ -80℃

Introduction/Overview

11-O-Syringylbergenin is a novel derivative of the rock cybage, first isolated from the whole plant of the traditional Chinese medicinal herb Bergenia crassifolia. As one of the hot topics in pharmacological research of natural products, cactinocylin and its derivatives have attracted widespread attention due to their diverse bioactivity. In recent years, 11-O-eugenyl rock cabbage extract has gradually become a research focus due to its significant anti-ulcer activity. Related studies have revealed that its effects involve multiple gastrointestinal protective targets, demonstrating promising potential for drug development. This paper aims to systematically review the chemical structure and physicochemical properties, plant origin and extraction methods, pharmacological activity and mechanism of action of 11-O-butyryl bedrock cabbagein, druggability evaluation, and pharmacokinetic characteristics, and to explore its clinical application prospects and future research directions.

Chemical structure and physicochemical properties

11-O-Eugenylyl Chlorophylin is a petroglycoloid esterified derivative with a molecular formula of C26H28O11 and a molecular weight of 508.4320. Its structural features include the ester bonding between the core backbone of the cylindrin group and the eugenyl group; the introduction of the eugenyl group not only increases the molecule's hydrophobicity, but may also affect its binding affinity with biological targets. In terms of physicochemical properties, the compound has a LogP value of 1.0443, indicating moderate lipid solubility, which facilitates cell membrane penetration without excessive hydrophobicity and affecting bioavailability. The polar surface area (TPSA) is 190.6700, indicating that the molecule has strong polar groups, which may affect its solubility and absorption characteristics. Water solubility is 1.5528, indicating a certain solubility in water, which is beneficial for developing oral administration routes. The low permeability of the blood-brain barrier suggests that this compound mainly acts on peripheral tissues, reducing the risk of central nervous system side effects. The hERG channel inhibition test was negative, indicating a low risk of cardiotoxicity. The Ames test scored 0.6, indicating a low genotoxicity risk and meeting safety requirements.

Plant Origins and Extraction Methods

11-O-Eugenyl Bedrock Cabbage Extract is mainly isolated from the whole Bergenia crassifolia plant. Dragon's Bone Grass is a perennial herbaceous plant of the Crassulaceae family, genus Dragon's Bone Grass, widely distributed in northern China and the Russian Far East. In traditional Chinese medicine, Longgu Grass is used to treat gastric ulcers, inflammation, and kidney diseases, and its medicinal value has been confirmed by modern pharmacology.

The extraction method typically uses alcohol extraction–liquid-liquid separation combined with column chromatography separation. The specific steps include: crushing the whole dried Longgu Grass plant, then reflux extraction using ethanol or methanol as a solvent. After concentration of the extract, use solvents such as ethyl acetate and n-hexane for separation. Subsequently, purification was performed using silica gel column chromatography and reversed-phase high-performance liquid chromatography (RP-HPLC), ultimately yielding high-purity 11-O-eugenyl bedrock cylindr. In recent years, the application of ultrasound-assisted extraction and microwave-assisted extraction technologies has improved extraction efficiency and purity, reduced solvent usage, and aligned with the concept of green chemistry.

Pharmacological activity research

Pharmacological activity studies of 11-O-Eugenyl Basein mainly focus on its anti-ulcer effect. Multiple in vivo and in vitro studies have shown that this compound can effectively inhibit gastric mucosal injury, promote ulcer healing, and has good safety.

In vivo models, 11-O-eugenyl rock-cyanin significantly alleviates the pathological manifestations of gastric ulcers caused by nonsteroidal anti-inflammatory drugs (NSAIDs), alcohol, and stress, manifesting as gastric mucosal bleeding, reduced erosion area, increased gastric juice pH, and increased gastric mucus secretion. Its anti-ulcer effect is comparable to commonly used clinical drugs such as rabeprazole and omeprazole, and has even shown superior efficacy in some experiments.

In vitro experiments have shown that this compound can regulate the secretory function of gastric mucosal cells, promote the expression of protective mucus component MUC5AC, and enhance the gastric mucosal barrier function. At the same time, 11-O-eugenyl rock cabyanin regulates gastric acid-related enzymes and receptors, exhibiting multi-target synergistic effects. In addition, antioxidant and anti-inflammatory activities are also important pharmacological foundations, helping to reduce oxidative stress and inflammatory responses in the gastric mucosa and promote tissue repair.

Mechanism of action and molecular targets

The anti-ulcer effect of 11-O-eugenyl rock cabbage involves multiple molecular targets, mainly including:

• PTGS1 (prostaglandin peroxide synthase 1, COX-1) and PTGS2 (COX-2): These compounds selectively regulate COX enzyme activity, promote prostaglandin synthesis, enhance gastric mucosal blood flow and secretion of protective mucus, and reduce NSAID-induced gastric mucosal injury.

• MUC5AC: As a major component of gastric mucus, upregulation of MUC5AC expression helps form a physical barrier that prevents stomach acid and digestive enzymes from eroding the stomach lining.

• GAST (gastrin) and its receptors CCKBR (cholecystokinin B receptor): 11-O-Cylindrin indirectly affects gastric acid secretion by regulating the expression of gastrin and its receptors, thereby maintaining a homeostatic stomach environment.

• SST (Somatostatin): This compound promotes the expression of somatostatin, inhibits excessive secretion of gastric acid, and protects the gastric mucosa.

• HRH2 (Histamine H2 receptor): Reduces histamine-induced gastric acid secretion by blocking or modulating H2 receptors, alleviating gastric mucosal damage.

• H+/K+-ATPase (proton pump): 11-O-Eugenyl Basein can inhibit the activity of proton pumps in gastric wall cells, reduce gastric acid secretion, and relieve ulcer symptoms.

• TGFα (Transforming Growth Factor α): Promotes proliferation and repair of gastric mucosal cells, aiding ulcer healing.

In summary, 11-O-butyryl bedrock cabbage extract regulates gastric acid secretion, strengthens the mucus barrier, inhibits inflammatory responses, and promotes tissue repair through multi-target and multi-pathway synergistic effects, exerting significant anti-ulcer activity.

Druggability evaluation and pharmacokinetics

From the perspective of druggability, 11-O-eugenyl bedrock cabyanin exhibits good medicinal properties. Its molecular weight is 508.4320, slightly above the 500 recommended by Lipinski's rules, but combined with its good water solubility (1.5528) and moderate LogP (1.0443), oral absorption is still expected to be feasible. A higher TPSA (190.6700) suggests stronger polarity, which may affect membrane permeability, but this also helps target local gastrointestinal effects and reduce systemic side effects.

The blood-brain barrier has low permeability, reducing the risk of central nervous system toxicity. hERG channel inhibition is negative, indicating a low risk of cardiotoxicity and meeting safety requirements. Ames trial results showed a low genotoxicity risk, further supporting its safety.

In terms of pharmacokinetics, related research is still in its early stages. In vivo metabolic kinetics experiments indicated that oral administration of 11-O-butyryl rocky cyanin resulted in higher local concentrations in the gastrointestinal tract and lower systemic circulation concentrations, consistent with its main effect on the gastric mucosa. Its metabolic pathways may involve hepatic esterase hydrolysis and gut microbial metabolism; the activity and toxicity of these metabolites require further study.

Prospects and outlooks for clinical applications

Given the multi-target effects and good safety of 11-O-eugenylyl chlorophyllin in the anti-ulcer field, its clinical application prospects are broad. Currently, gastric ulcer treatment mainly relies on proton pump inhibitors (PPIs) and H2 receptor antagonists, but long-term use faces issues such as drug resistance, drug interactions, and side effects. As a natural product derivative, 11-O-eugenyl rock-based cabyanin exhibits multi-mechanism synergistic effects and may overcome the limitations of existing drugs.

Future research should focus on the following aspects:

1. Preclinical safety and toxicology studies: Systematic evaluation of the safety of long-term medication, clarifying maximum tolerated doses and potential toxicity.

2. Pharmacokinetic-pharmacodynamic relationship (PK/PD) studies: clarify absorption, distribution, metabolism, and excretion characteristics in vivo to optimize administration regimens.

3. Dosage form development and delivery route optimization: Explore oral sustained-release formulations or gastric mucosa-targeted delivery systems to improve efficacy and patient compliance.

4. Clinical trial design: conduct randomized, double-blind, controlled clinical trials to verify efficacy and safety, and promote clinical translation.

5. Structural modification and derivative development: Based on the 11-O-eugenyl bedrock cylindrin backbone, more derivatives are designed and synthesized to optimize pharmacodynamics and pharmacokinetic properties.

Moreover, the compound has potential for anti-inflammatory and antioxidant pharmacological activities and may expand its indications.

Conclusion

11-O-Eugenyl Rock Cabbage Extract, as a derivative derived from Longgu Grass, demonstrates promising drug development potential due to its unique chemical structure and multi-target anti-ulcer effects. Its moderate physicochemical properties, good safety, and significant gastric mucosal protective effects provide new ideas and candidate molecules for developing novel anti-ulcer drugs. In the future, through systematic pharmacological mechanism research, druggability optimization, and clinical validation, it is expected to become an effective drug for clinical use, benefiting a wide range of ulcer patients. The field of natural product pharmacology should continue to strengthen research on these compounds, promoting the modern transformation and innovative development of traditional Chinese medicinal resources.